While our results for the competing risk group with high amounts of AD neuropathology agree with the mortality risk results of these previous studies, our observed association of decreased mortality risk in APOE4 carriers with low amounts of AD neuropathology at death are contradictory to reported findings of the existing studies. The gene discussed is APOE; the disease is Alzheimer disease.